(688765)"WUHAN HEALTHGEN BIOTECHNOLOGY CORP."Report for Q3 2026
Filed with SSE · Stock code 688765 · · 13 pages · Chinese
Summary by 6ix AI
The report highlights that the financial statements have not been audited and includes key financial data such as revenue and net profit figures. It also discusses the company's ongoing clinical trials and research projects, particularly focusing on the drug 奥福民 and its development progress. The report emphasizes the company's commitment to transparency and accuracy in its financial disclosures and operational updates.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Wuhan Healthgen Biotechnology Corp on 6ix
Earlier from Wuhan Healthgen Biotechnology
- (688765)"WUHAN HEALTHGEN BIOTECHNOLOGY CORP."Announcement on Listing and Trading of Certain Restricted Shares from the Initial Public Offering and Certain Restricted Shares from the Strategic Placement
- Announcement on Pledge and Release of Pledge of Certain Shares Held by Shareholder Holding More Than 5% of the Shares
- "WUHAN HEALTHGEN BIOTECHNOLOGY CORP."2026 Semi-annual Continuous Supervision and Guidance Follow-up Report of GUOTAI HAITONG SECURITIES CO., LTD. on WUHAN HEALTHGEN BIOTECHNOLOGY CORP.
- Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
- Semi-annual Report for 2026
Later from Wuhan Healthgen Biotechnology
- (688765)"WUHAN HEALTHGEN BIOTECHNOLOGY CORP."Announcement on the Commitment by the Controlling Shareholder and Actual Controller to Extend the Lock-up Period of the Shares Held in the Company
- (688765)"WUHAN HEALTHGEN BIOTECHNOLOGY CORP."Announcement on Voluntary Disclosure of the Inclusion of the Company's Recombinant Human Albumin Injection (Oryza sativa) in the 2026 National Reimbursement Drug List
Follow Wuhan Healthgen Biotechnology into a list and get an email when it puts out news.
Follow Wuhan Healthgen Biotechnology